MA-REINVEST-ROBOTICS
The European Commission’s proposed AI Act and updated regulations on machinery products will cause severe damage to European small businesses, robotics companies and innovation, according to four of the most influential voices in robotics and automation. Together, the International Federation of Robotics , the VDMA Robotics + Automation Association , EUnited Robotics and REInvest Robotics urgently call on European policymakers to revisit and amend the proposals.
While all four organizations embrace the European Commission’s vision to maintain safety, protect human rights and create a harmonized framework for artificial intelligence and robotics, the collective sees the following primary issues with the proposed regulations as currently drafted:
- The mandatory third-party certification requirements will slow tech innovation across Europe.
- The restrictions will hinder artificial intelligence adoption and put European companies, especially SMEs and startups, at a competitive disadvantage globally.
- Disruption risk to regional supply chain, manufacturing and logistics operations will rise if the proposals are implemented and adopted.
- Compliance with regulation worldwide will become more complex and burdensome.
Dr. Susanne Bieller, General Secretary of the International Federation of Robotics, states, “The International Federation of Robotics calls on European policymakers to amend both drafts to balance the protection of citizens with the market’s need to adopt new technologies and ensure a level-playing field for companies. This is not purely a European issue, as the proposed regulations will severely impact all companies bringing robots to the European market. In the long run, the new regulations will be to the disadvantage of European companies, especially SMEs and startups.”
Patrick Schwarzkopf, Managing Director of the VDMA Robotics + Automation Association and Director of EUnited Robotics, comments: “The EU-Commission’s proposals include burdensome regulations of so-called ‘High-Risk AI’ and ‘High-Risk-machinery.’ They include the introduction of extensive mandatory third-party certification requirements, which will discourage the use of AI and slow down innovation across Europe.”
Dr. Esben Hallundbæk Østergaard, the CEO of REInvest Robotics and founder of Universal Robots, comments: “The proposed legislation will hold back European robotics innovation. This is particularly concerning given robotics is the one emerging tech segment where Europe still has an edge globally. Locally, the legislation will negatively affect thousands of small businesses, factories, and manufacturers that rely on robotics and AI to automate critical operations and overcome labor shortages.”
Recommended policy amendments include limiting the scope of the AI Act to essential human rights risks, relying on manufacturers’ self-declaration of conformity in both the AI-Act and Regulation on Machinery Products, increasing enforcement and governance of the existing approach of the machinery directive, and working to create a global framework that increases safety and ethics while maintaining a level playing field. The recent draft report published on the Regulation on Machinery products by the European Parliament’s Committee on Internal Market and Consumer Protection (IMCO) points in this direction by proposing to uphold the crucial principle of self-declaration.
“The approach of the current machinery directive is sufficient. The problem is with governance. We recommend focusing on ensuring that products on the market actually comply with the current EU law, not creating new regulations,” said Østergaard.
For more info, visit reinvestrobotics.com and watch Patrick Schwarzkopf and Dr. Esben Hallundbæk Østergaard discuss the proposals: https://youtu.be/cd0VQx6w-wQ
About REInvest Robotics
REInvest Robotics is a specialized accelerator that invests in startups that democratize the use of robotics to solve real world problems. Founded by robotics pioneer and inventor Esben Hallundbæk Østergaard and Richa Hallundbæk Misri, REInvest Robotics’ vision is to fuel the robotics ecosystem with sustainable investments and help entrepreneurs uplift humankind through robotics. The firm – which provides seed funding and advisory services – specializes in robotics, AI, manufacturing, safety standards and legislation. Successful investments include market leaders Universal Robots and Mobile Industrial Robots (MiR). Learn more at https://www.reinvestrobotics.com/ and follow REInvest Robotics on LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211208005149/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ImmunAbs Announces FDA Phase 2 IND Approval of IM-101, a Novel Complement C5 Inhibitor, for Treatment of Myasthenia Gravis2.6.2025 13:00:00 CEST | Press release
ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial evaluating the safety and efficacy of IM-101, a novel complement C5 inhibitor, for the treatment of Myasthenia Gravis. The forthcoming multicenter, randomized, double-blind, placebo-controlled study will enroll up to 90 patients to evaluate the effectiveness and safety of monthly IM-101 dosing in relieving complement-induced symptoms in MG. “This IND approval is pivotal for us as it brings us one step closer to delivering a transformative therapy for patients with autoimmune disorders”, said Dr. Dongjo Kim, the CEO of ImmunAbs, “we believe IM-101 has the potential to deliver deeper therapeutic responses and more durable remissions in patients who have failed to achieve sustained remission with current approved treatment.” About Myasthenia Gravis
Lenovo and Bellevue University Team Up to Offer Supply Chain and Logistics Education to Deliver “Smarter Technology for All”2.6.2025 13:00:00 CEST | Press release
Learners will have access to Lenovo’s globally recognized supply chain expertise through real-world case studies and subject matter experts. Lenovo, the global technology powerhouse, recognized in the top 10 in the Gartner Supply Chain Top 25, and Bellevue University, one of the nation’s top online universities, are teaming up to develop the next generation of supply chain professionals. “We believe that bringing real-world Global Supply Chain experience and learning directly into an education curriculum is precisely the optimal way to upskill the workforce of the future,” said Ben Massie, Vice President, Global Supply Chain, Lenovo. “Teaming up with Bellevue allows us to attract the right talent using the right technology and deliver on our mission to make ‘smarter technology for all’ a reality.” As a preferred higher education institution tapped to team up with Lenovo to offer supply chain short-term learning, Bellevue will leverage the breadth and depth of Lenovo’s supply chain expe
Lifezone Metals Files Initial Assessment for the Kabanga Nickel Project in Tanzania2.6.2025 12:30:00 CEST | Press release
Vertically Integrated Plan includes Hydrometallurgical Refinery at Kahama $2.37 Billion After-Tax NPV (8%) and 22.9% After-Tax IRR at $8.49 per Pound Nickel Price Initial Assessment Proposes a 22-Year Mine Plan at Average 2.39% Nickel Equivalent Grade Webcast with Technical Leadership Team at 10 AM ET on Tuesday, June 3, 2025 Lifezone Metals Limited’s (NYSE: LZM) Chief Executive Officer, Chris Showalter, and Chief Operating Officer, Gerick Mouton, announce today the results from the Initial Assessment for its flagship Kabanga Nickel Project in northwest Tanzania. The Initial Assessment evaluates a vertically integrated mining, processing and refining operation, commencing with a high-grade nickel sulfide underground mine and concentrator at the Kabanga site, followed five years later by a hydrometallurgical refinery at Kahama. The study covers the Main, MNB, Kima, North, and Tembo zones and is based on the December 2024 Mineral Resource Update (refer to Lifezone’s December 5, 2024 news
Corpay Cross-Border Named an Official Partner of Real Madrid C.F.2.6.2025 12:00:00 CEST | Press release
Providing access to currency risk management and cross-border payments solutions Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, is pleased to announce that Corpay’s Cross-Border business has entered into an agreement with Real Madrid C.F. to become an Official Partner. Through this partnership, Real Madrid will be able to gain access to and utilise Corpay Cross Border’s innovative solutions to help mitigate foreign exchange exposure from their day-to-day business needs. "The Corpay Cross-Border team is elated to be named an Official Partner of Real Madrid, one of the world’s most widely recognized and followed sports franchises," said Brad Loder, Chief Marketing Officer, Corpay Cross-Border Solutions. “With our strong focus on growing the Corpay brand, as well as our currency risk management business, we are excited to partner with one of the most successful football clubs in the world.” About Corpay Corpay, Inc. (NYSE: CPAY) is a global S&P500 corporate payments co
BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 20252.6.2025 12:00:00 CEST | Press release
Preliminary results highlight anti-tumor activity and favorable safety profiles of both B7-H4-targeting ADC and CDK2 inhibitorData underscore strength of emerging breast cancer pipeline as part of BeOne’s global transformation with next wave of innovation BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, announced new clinical data from its emerging breast cancer pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Poster presentations feature preliminary results of the dose escalation studies of two investigational molecules: BG-C9074, a novel B7-H4-targeting antibody-drug conjugate (ADC) in patients with advanced solid tumors, including breast cancer, and BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), in HR+/HER2- breast cancer patients with prior CDK4/6i exposure. “Presenting the first clinical data for two novel breast cancer candidates at ASCO 2025 marks a pivotal moment for BeOne,” said Mark Lanas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom